Flutiform fluticasone propionate/formoterol: Phase III data

Top-line data from the double-blind, international Phase III EFFECT trial in 1,767 COPD patients ages >=40 showed that twice-daily 250/10 ug inhaled flutiform for 52 weeks missed the primary endpoint ...